Bristol Myers Squibb News

Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.

Bristol-Myers Squibb's Joseph Campisi and Demetrios Kyonieus were virtually inseparable for eight months in 2012 while they negotiated an M&A deal that was large and complex.

Bristol-Myers Squibb Company will present at the UBS Global Health Care Conference on Tuesday, May 21, 2013, in New York City.

This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.

BT announced the appointment of Bas Burger to the position of president of BT US & Canada and president for the Global Consumer Packaged Goods and the Global Pharmaceutical and Chemical industry sectors.

Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response.

Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of the its recent shareholder meeting.

Approval offers a once-daily option as part of a regimen for HIV-1 infected infants as young as three months and weighing at least 3.5 kg.

ObamaCare Developments Could Have Major Impact on Leading Drugmaker Bristol-Myers Squibb Executive Tells National Center for Public Policy Research that the Company is Following IPAB Creation "Very Closely" Obama Administration "Dual-Eligibles" Rebate Plan, if Imposed, Could Have "Significant Impact" During "Pivot Year" for Bristol-Myers Squibb ... (more)

ARISTOTLE studied Eliquis vs. warfarin for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation )-- Bristol-Myers Squibb Company and Pfizer Inc .

Ambrx and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA , including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

However, the company is not involved only in the manufacturing and sales of medicines in Mexico, but participates in other areas such as powder hot drinks with the very successful brands Cal-C-Tose and Choco Milk.

The firm currently has a "market perform" rating on the company's shares. Several other analysts have also recently commented on the stock.

The firm currently has a "sell" rating on the stock. The analysts noted that the move was a valuation call.

's stock had its "neutral" rating reiterated by equities research analysts at JPMorgan Chase in a research note issued to investors on Friday, AnalystRatingsNetwork.com reports.

Time Warner Cable, Bristol-Myers Squibb, and JetBlue earnings announcements disappointed Wall Street, while Colgate-Palmolive and New York Times stock gained despite profit declines.

Bristol-Myers Squibb is scheduled to announce its results for Q1 2013 on April 25.

Bristol-Myers Squibb is expected to report earnings on Thursday, April 25th. The whisper number is $0.45, four cents ahead of the analysts' estimate.

The US FDA is beginning to push CMOs and other manufacturers away from using real-time release testing as a shortcut to ensuring drug quality and reducing end product testing, experts said.